---
title: Image Parkinson related brain protein
nct_id: NCT07604116
phase: PHASE1
status: RECRUITING
sponsor: Synusight Biotech (Shanghai) Co., Ltd.
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07604116"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07604116"
last_fetched: "2026-06-30T14:01:35.915Z"
source: "Parkinson's Pathways (curated)"
---
# Image Parkinson related brain protein

**Goal (in five words):** Image Parkinson related brain protein

**Official Title:** A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease

**Trial ID:** [NCT07604116](https://clinicaltrials.gov/study/NCT07604116)

## Key Facts

- **Phase:** PHASE1
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Synusight Biotech (Shanghai) Co., Ltd.
- **Target Enrollment:** 30 participants
- **Start Date:** 2026-06-15
- **Completion Date:** 2026-12
- **Conditions:** Multiple System Atrophy (MSA), Parkinson's Disease (PD)
- **Interventions:** SST001
- **Intervention Types:** DRUG

## Summary For Families

Goal: to find out whether a new brain imaging tracer called SST001 is safe and well tolerated and to learn where it goes in the body, how the body processes it, and what radiation dose it gives. Approach: participants will receive a very small dose of SST001, labeled with fluorine-18, and have positron emission tomography (PET) scans to see if the tracer can detect alpha-synuclein pathology, a hallmark of Parkinson's disease and multiple system atrophy. Eligibility: adults aged 40 and older, including healthy volunteers and people diagnosed with Parkinson's or multiple system atrophy (if on treatment, the regimen must be stable for at least four weeks); common exclusions include pregnancy, serious other medical or neurological problems, active infections, inability to tolerate required scans (for example PET/CT or magnetic resonance imaging), recent interventional trial participation, or prior therapies targeting alpha-synuclein.

## What This Actually Involves

**Placebo** _(From the protocol)_: Everyone in this trial receives the experimental treatment. There is no placebo group.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(Ask the coordinator)_: Ask the coordinator what tests and procedures are involved, for example blood draws, scans, or questionnaires, and whether any are uncomfortable or invasive.

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Sign the informed consent form approved by IEC.
* Male or female participants aged ≥40 years old.
* Adequate organ functions.
* Proper contraception methods.
* Willingness to follow the study procedures.
* Additional inclusion criteria for healthy volunteers: Good health status; no history of motor disorders or cognitive disorders.
* Additional inclusion criteria for MSA: Diagnosed with clinically established or clinically probable MSA according to the MDS MSA criteria (2022). If previously treated, the treatment regimen for MSA must have been stable for at least 4 weeks with no planned adjustments in the near term.
* Additional inclusion criteria for PD: Diagnosed with clinically established or clinically probable PD according to the MDS PD criteria (2015). If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.

Exclusion Criteria:

* Being pregnant or lactating.
* History of other severe neurological disorders.
* History of serious or uncontrolled medical condition.
* Active HBV/HCV/HIV infection, etc.
* History of abuse of drugs or alcohol within 1 year.
* Allergy to the study drug.
* Intolerance to PET/CT or MRI (e.g. claustrophobia).
* Any interventional clinical studies within 30 days.
* Radiation exposure dose exceeding 50 mSv/year.
* Prior therapy targeting α-Syn.
* Other ineligible conditions for this study.
```

## Locations (2)

- Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China _(31.5689, 120.2886)_
  - Jing Chun Yu, Professor, (CONTACT), +86 0510-68089401, ycjwxd1978@jiangnan.edu.cn
- Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Jian Wang, Professor, (CONTACT), +86 021-52888163, wangjian336@hotmail.com

## Central Contacts

- Jian Wang, Professor, (CONTACT), +86 021-52888163, wangjian336@hotmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07604116*  
*HTML version: https://parkinsonspathways.com/trial/NCT07604116*  
*Source data: https://clinicaltrials.gov/study/NCT07604116*